| Autor: |
Spark RF; Department of Medicine, Beth Israel Hospital, 330 Brookline Avenue, Boston, MA 02215, USA. rspark@bidmc.harvard.edu |
| Jazyk: |
angličtina |
| Zdroj: |
Current urology reports [Curr Urol Rep] 2007 Nov; Vol. 8 (6), pp. 467-71. |
| DOI: |
10.1007/s11934-007-0050-4 |
| Abstrakt: |
Metabolic syndrome is characterized by insulin insensitivity, central obesity dyslipidemia, and hypertension. It is recognized as a risk factor for cardiovascular disease in men; by the time metabolic syndrome is diagnosed, however, most men already have entrenched cardiovascular disease. A reliable early warning sign is needed to alert physicians to those at risk for metabolic syndrome and cardiovascular disease. Low serum testosterone level has emerged as a reliable prognosticator of metabolic syndrome in men whose testosterone deficiency is genetic (Klinefelter syndrome), iatrogenic following surgery for testicular cancer, pharmacologically induced by gonadotropin-releasing hormone during prostate cancer treatment, or a natural consequence of aging. One third of men with type 2 diabetes mellitus are now recognized as testosterone deficient. Emerging evidence suggests that testosterone therapy may be able to reverse some aspects of metabolic syndrome. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink